Biosapogen to develop antineoplastic agent containing ingredients of ginseng

Published: 2003-08-28 06:56:00

Updated: 2003-08-28 06:56:00

Korea Green Cross Sang-A said that its affiliated company Biosapogen, bioventure firm having differentiated gensenoside, is economically producing Rh2 and Rg3, which are contained in a wild ginseng as small amounts, on a large scale using a bio-transformation technique designed to extract Rh2 and...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK